GlobeNewswire: Arog Pharmaceuticals, Inc. Contains the last 10 of 13 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:24:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/06/06/1518084/0/en/Arog-Pharmaceuticals-Announces-Clinical-Presentations-on-Crenolanib-at-the-23rd-Congress-of-the-European-Hematology-Association.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Announces Clinical Presentations on Crenolanib at the 23rd Congress of the European Hematology Association2018-06-06T22:19:17Z<![CDATA[DALLAS, June 06, 2018 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that it will feature two poster presentations on the company’s lead product candidate, crenolanib, at the 23rd Congress of the European Hematology Association (EHA), taking place June 14-17, 2018 in Stockholm, Sweden.]]>https://www.globenewswire.com/news-release/2017/12/05/1228982/0/en/Arog-Pharmaceuticals-Announces-Oral-Presentation-on-Crenolanib-at-the-2017-American-Society-of-Hematology-Annual-Meeting.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Announces Oral Presentation on Crenolanib at the 2017 American Society of Hematology Annual Meeting2017-12-05T12:00:00Z<![CDATA[DALLAS, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that it will present data on its lead product candidate, crenolanib, at the 59th American Society of Hematology (ASH) Annual Meeting, taking place December 9-12, 2017 in Atlanta, GA. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations.]]>https://www.globenewswire.com/news-release/2017/12/01/1216122/0/en/Arog-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-Crenolanib-in-Relapsed-or-Refractory-FLT3-Positive-AML.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib in Relapsed or Refractory FLT3-Positive AML2017-12-01T12:00:00Z<![CDATA[DALLAS, Dec. 01, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for crenolanib for the treatment of patients with FLT3 mutation-positive relapsed or refractory acute myeloid leukemia.]]>https://www.globenewswire.com/news-release/2017/06/12/1017907/0/en/Arog-Pharmaceuticals-Announces-Clinical-Presentations-on-Crenolanib-at-the-22nd-Congress-of-the-European-Hematology-Association.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Announces Clinical Presentations on Crenolanib at the 22nd Congress of the European Hematology Association2017-06-12T17:52:37Z<![CDATA[DALLAS, June 12, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that it will feature two poster presentations and a satellite symposium on the company’s lead product candidate, crenolanib, at the 22nd Congress of the European Hematology Association (EHA), taking place June 22-25, 2017 in Madrid, Spain. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations.  ]]>https://www.globenewswire.com/news-release/2017/05/22/994570/0/en/Arog-Pharmaceuticals-Presents-Crenolanib-Clinical-Data-at-the-2017-American-Society-of-Clinical-Oncology-Annual-Meeting.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2017 American Society of Clinical Oncology Annual Meeting2017-05-22T11:04:00Z<![CDATA[DALLAS, May 22, 2017 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that it will feature two clinical poster presentations on the company’s lead product candidate, crenolanib, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2017 in Chicago. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations.]]>https://www.globenewswire.com/news-release/2016/11/21/891873/0/en/Arog-Pharmaceuticals-Receives-Orphan-Drug-Designation-in-the-European-Union-for-Crenolanib-for-the-Treatment-of-Acute-Myeloid-Leukemia-and-Soft-Tissue-Sarcoma.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Receives Orphan Drug Designation in the European Union for Crenolanib for the Treatment of Acute Myeloid Leukemia and Soft Tissue Sarcoma2016-11-21T21:30:00Z<![CDATA[DALLAS, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation for its lead product candidate, crenolanib, for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma.]]>https://www.globenewswire.com/news-release/2016/11/16/890714/0/en/Arog-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-Crenolanib-for-Advanced-Gastrointestinal-Stromal-Tumors-with-a-D842V-Mutation-in-the-PDGFRA-Gene.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene2016-11-16T21:30:00Z<![CDATA[DALLAS, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for crenolanib for the treatment of patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRα) D842V mutation.]]>https://www.globenewswire.com/news-release/2016/11/07/887530/0/en/AROG-Pharmaceuticals-to-Present-Clinical-Data-on-Crenolanib-at-the-2016-American-Society-of-Hematology-Annual-Meeting.html?f=22&fvtc=4&fvtv=25885AROG Pharmaceuticals to Present Clinical Data on Crenolanib at the 2016 American Society of Hematology Annual Meeting2016-11-07T21:30:00Z<![CDATA[DALLAS, Nov. 07, 2016 (GLOBE NEWSWIRE) -- AROG Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced its abstract highlighting the company’s lead product candidate, crenolanib, in a combination study with cytarabine and anthracycline has been selected for an oral presentation at the 2016 American Society of Hematology (ASH) annual meeting. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations. In addition, AROG will present three posters on its combination studies of crenolanib with sorafenib, idarubicin and high-dose ara-C (HiDAC), and high-dose ara-C and mitoxantrone (HAM) in AML patients with FLT3 mutations. The ASH annual meeting will take place December 3-6, 2016 in San Diego, California. Details of the abstract presentations are provided below.]]>https://www.globenewswire.com/news-release/2016/05/24/842731/0/en/Arog-Pharmaceuticals-Presents-Crenolanib-Clinical-Data-at-the-2016-American-Society-of-Clinical-Oncology-Annual-Meeting.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting2016-05-24T11:00:00Z<![CDATA[DALLAS, May 24, 2016 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that its abstract highlighting the company’s lead product candidate, crenolanib, has been selected for oral presentation in a plenary session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Crenolanib continues to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations. In addition, Arog will present a poster on its dose escalating study of crenolanib besylate in advanced GIST patients with PDGFRA D842V activating mutations.]]>https://www.globenewswire.com/news-release/2015/12/09/794097/10158194/en/Arog-Pharmaceuticals-Presents-Crenolanib-Clinical-Data-at-57th-American-Society-of-Hematology-Annual-Meeting.html?f=22&fvtc=4&fvtv=25885Arog Pharmaceuticals Presents Crenolanib Clinical Data at 57th American Society of Hematology Annual Meeting2015-12-09T13:00:00Z<![CDATA[DALLAS, Dec. 9, 2015 (GLOBE NEWSWIRE) -- Arog Pharmaceuticals, Inc., a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, today announced that clinical data from its lead product candidate, crenolanib, continue to demonstrate best-in-class properties in the treatment of acute myeloid leukemia (AML) with FLT3 mutations. Analyses from Phase II clinical studies of crenolanib were presented at the 57]]>